Aerogen, Irelands largest indigenous Medtech company and a World Leader in hospital-based Aerosol Drug Delivery1† today celebrates the production of its 20th million Aerogen Solo1. The multi-award-winning Aerogen Solo product is globally used by hospital caregivers to aerosolise drugs for the acutely compromised respiratory patient.
This milestone is jointly celebrated with the company’s 25th anniversary. From humble beginnings in a room above a butcher’s shop in the West of Ireland, the company has grown and expanded its reach, now supporting customers and patients in over 75 countries around the world1.
Headquartered in Galway with manufacturing in Parkmore and Shannon, Aerogen’s workforce has tripled in the past five years to 500 employees operating in 28 countries. This hugely successful Irish company continues its expansion with 110 new employees introduced in 2023 and a further 50 multi-disciplined positions recently announced.
Speaking at Aerogen’s milestone event at their plant in Parkmore, Minister Neale Richmond TD said: “I am delighted to join Aerogen at their highly impressive facility here in Galway to witness the production of the 20 millionth Aerogen Solo device. Irish businesses like Aerogen are the backbone of our economy, scaling and growing their footprint overseas, while continuing to develop and nurture the team back home. I am delighted that Aerogen, an Enterprise Ireland supported company which started its life back in 1997, has now grown to be an international player on the world stage working with and developing lifesaving respiratory devices and clinical products for the health sector globally.
Today’s milestone anniversary is a testament to the talent of all of Aerogen’s staff. The work and dedication of the team was particularly apparent during the pandemic when life-saving products including the Aerogen Solo device were used to treat, and continues to treat, Covid-19 patients worldwide. I would like to congratulate John Power and his team and wish them the very best for the future,” the Minister concluded.
Leo Clancy, CEO, Enterprise Ireland said; “I would like to congratulate Aerogen on their 25th anniversary and producing their 20 millionth device. This great Irish medtech company has gone from strength-to-strength, establishing a strong presence in international markets, creating and sustaining high quality jobs here in the West of Ireland, while continuing to invest in innovation. I wish John, Brendan and all the team the very best for the future. Enterprise Ireland looks forward to continuing to work with the company on their growth trajectory, improving the outcomes for so many respiratory patients and their families right across the globe for the next 25 years and beyond.”
"The 20 millionth product is an incredible milestone for us to achieve during our 25 year celebrations” said John Power, Aerogen CEO and Founder. "Our journey has been marked by relentless dedication to innovation led and customer-centric solutions and whilst we today rightly celebrate a production milestone, we also reflect on the acutely sick patients those products have played a key role in treating. To be able to impact the clinical outcome for one person is a great privilege, to be involved in the treatment of 20 million individual patients globally is not alone a huge privilege but also an incredible honour for us all at Aerogen".
The 20 millionth Aerogen Solo was packaged in a unique, gold branded box. The customer that receives this shipment will be acknowledged with a €10,000 donation to the charity of their choice. (T&C apply)
As part of their 25th-anniversary celebration, Aerogen has planned a series of 25 events and initiatives to express its gratitude to its employees, customers and the communities in which they operate. The company has donated over €100,000 to various charities and organisations already this year with plenty more activity planned.
Headquartered in Galway, Aerogen is a world leader in acute care aerosol drug delivery1†. With a global team of 500 people the company has offices in the US, China, Germany, UAE, France, and India. With over 25 years of experience, 300 international patents, and 200+ publications1, Aerogen technology has been used to treat over 16 million patients in 75 countries worldwide1.
Aerogen’s parent company Stamford Devices Limited Group, reported a strong financial performance for the year ending 31st December 2022, recording €119.9 million in revenue. Sales in Aerogen’s core Medical Device business of €117 million resulted in EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of €26.5 million.
As a recognised innovation and technology pioneer Aerogen once again increased investment in Research & Development to €18.5 million in 2022, up 12.7% YoY (year on year). Overall OPEX (operating expense) increased by 20% to €69.6 million reflecting the significant R&D Spend, Commercial expansion, and funding for the company’s ongoing proprietary drug clinical trials in the US.
Talent management continues to be at the forefront of the Aerogen success story and this is evident by further investment in people in 2022. Year on year organic growth had seen the headcount in the group reach 446 direct employees by the end of 2022, an increase of 23.8% in 2022. Increased headcount was predominantly to support global expansion with further additions in Engineering and support staff based out of the Galway HQ.
For more information about Aerogen's achievement and its ongoing work in the medtech sector, please visit aerogen.com or contact firstname.lastname@example.org
1. Aerogen data on file
† Global market presence in 75 countries